In May, the company announced the failure of the monoclonal antibody birtamimab to improve mortality in a phase 3 trial of ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Prothena Corp shares climbed 5% in after-hours trading on Friday after the company said it expects to reduce its 2025 net ...

Prothena will cut 63% of its workforce and evaluate a “range of business options.” Elsewhere, Zealand revealed data for a ...

Prothena Corporation plc (NASDAQ:PRTA) is among the best NASDAQ stocks under $50 to buy. Roche, a partner of Prothena ...

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...

Why California wants to stop 23andMe's sale to former CEO How a Peninsula company is brewing cheaper Narcan in the U.S. How a ...

Prothena announced partner Roche will advance prasinezumab into Phase III development in early-stage Parkinson’s disease.

Prothena said it would reduce its workforce after a recent trial failed to meet its primary and secondary endpoints. The Irish biotechnology company is planning a "substantial" job cut as it aims ...

DUBLIN--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation ...

Prothena plans to present results from the Phase 1 SAD study at an upcoming medical conference. These results support the ongoing Phase 1 MAD trial of PRX005 in patients with Alzheimer’s disease.